Red Hill to proceed with Phase 3 trial

The FDA clears Red Hill Biopharma's (RDHL) IND amendment allowing it to initiate a Phase 3 clinical trial for a new indication of RHB-102, a once-daily extended release oral formulation of the antiemetic drug ondansetron. Patient enrollment for the 320-subject eight-site U.S. trial will be begin in Q3.

In parallel, the company is pursuing marketing approval for the use of RHB-102 for chemotherapy and radiotherapy-induced nausea and vomiting in the U.S. and Europe.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs